FOXO4-DRI (10mg)

FOXO4-DRI is a D-retro-inverso (DRI) peptide designed to interfere with the FOXO4-p53 protein-protein interaction in senescent cells. The DRI modification reverses the peptide sequence and substitutes D-amino acids for L-amino acids, conferring enhanced proteolytic stability while maintaining the side-chain topology required for target binding. This engineered stability makes FOXO4-DRI a significant research tool in the field of cellular senescence.

Research has focused on FOXO4-DRI's ability to selectively disrupt the FOXO4-p53 complex that maintains senescent cell viability. In preclinical studies, investigators demonstrated that senescent cells rely on FOXO4-mediated sequestration of p53 to resist apoptosis. By competitively binding FOXO4 and displacing p53, the DRI peptide has been investigated for its ability to restore p53-dependent apoptotic signaling specifically in senescent cells while sparing non-senescent populations. Landmark publications in Cell (2017) documented these findings in naturally aged murine models, where researchers observed selective clearance of senescent cells.

The mechanism involves competitive inhibition of the FOXO4 interaction domain that normally sequesters p53 in PML nuclear bodies. Released p53 then activates its canonical mitochondrial apoptotic pathway (Bax/Bak, cytochrome c release, caspase cascade) selectively in cells exhibiting the senescence-associated secretory phenotype.

Viking Labs synthesizes this complex DRI peptide at a USA-based cGMP facility. HPLC verification confirms 99%+ purity. COA included, batch serialized, sterile filled.

Storage: Store lyophilized at -20C. Reconstituted at 2-8C, use within 14 days due to DRI peptide stability characteristics.

For laboratory research use only. Not for human consumption.